Related Experiment Video
Updated: Nov 21, 2025

Automated Acoustic Dispensing for the Serial Dilution of Peptide Agonists in Potency Determination Assays
Published on: November 10, 2016
The Design of a GLP-1/PYY Dual Acting Agonist
Søren Østergaard1, Johan F Paulsson2, Marina Kjaergaard Gerstenberg2
1Global Research Technologies, Novo Nordisk Research Park, 2760, Maaloev, Denmark.
Abstract:
The two gut hormones GLP-1 and PYY3-36 , which are both secreted from the L-cells upon food stimuli, have a stronger inhibitory effect on food intake when they are combined, compared to their individual effects as single agonists. Although they are not homologous and share no sequence similarity, we show that a GLP-1 analogue can be designed to exhibit potent activity on both the Y2 and GLP-1 receptors. Dual acting hybrid analogues were realized by designing truncated and potent Y2 receptor PYY analogues, followed by integrating the critical residues into GLP-1. In this study, we show that one of these dual acting agonists acutely reduces food intake significantly more than the respective mono-agonist counterparts.
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Oral Hypoglycemic Agents: Glinides
Dipeptidyl Peptidase 4 Inhibitors
Oral Hypoglycemic Agents: Biguanides and Glitazones
GPCRs Regulate Adenylyl Cylase Activity
Oral Hypoglycemic Agents: Sulfonylureas

